Defines medical necessity criteria, documentation, and approval length for CFTR-modulator drugs and inhaled aztreonam for individuals with cystic fibrosis; applies to pharmacy benefit management.
Policy Summary
PayerPremera Bluecross
PolicyPharmacologic Treatment of Cystic Fibrosis
Policy CodePolicy N/A
Change TypeMaterial updates to coverage criteria and authorization length
Effective DateApr. 1, 2026
Next Review DateN/A
Key ActionObtain and submit CFTR genotype documentation showing a mutation listed as responsive to the requested CFTR modulator for prior authorization.
Orkambi and other product age indications were updated over time (2015-2018) to reflect lower approved ages (down to 2 years for some products).
Symdeko labeling updated in 2019 to age 6 years and older and in 2020 to remove CFTR mutation R117H from the responsive list.
Added coverage criteria for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor).
Updated Trikafta coverage criteria to include treatment of certain individuals with mutations responsive based on clinical and/or in vitro data.
Updated initial approval length from 6 months to 12 months.
Added product-specific quantity limits and enforced limits per prescribing information.
12 monthsinitial approval duration
Alyftreknewly added medication
≥6 yrs
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
minimum age (Alyftrek/Symdeko)
≥2 yrsminimum age (Trikafta)
25–75%FEV1 coverage range (Cayston)
clinical/in vitroTrikafta mutation coverage
Coverage Criteria for CFTR Modulators and Inhaled Aztreonam
Alyftrek initial criteria: The individual is aged 6 years and older AND has at least one F508del mutation in the CFTR gene OR another responsive CFTR mutation (see Related Information) AND does not have liver function tests (LFT) above 3X upper limit of normal (ULN) AND Alyftrek will not be used in combination with Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), or Trikafta (elexacaftor/tezacaftor/ivacaftor) AND dose is limited to three tablets of a fixed-dose combination containing vanzacaftor 4 mg/tezacaftor 20 mg/deutivacaftor 50 mg OR two tablets of a fixed-dose combination containing vanzacaftor 10 mg/tezacaftor 50 mg
Cayston initial criteria: The individual is aged 7 years and older to improve respiratory symptoms in cystic fibrosis AND has a known Pseudomonas aeruginosa infection AND the FEV1 is between 25% to 75% predicted AND quantity is limited to 3 vials per day (one 75 mg single-use vial administered three times daily)3 vials/day; FEV1 25-75% predicted
Adhere to product prescribing information for administration
Kalydeco (ivacaftor) — Initial therapy
Covered when ALL of the following are met
Kalydeco initial criteria: The individual is aged 1 month and older AND has one of the CFTR gene mutations listed in the policy table or any CFTR gene mutation subsequently added to the FDA-approved indication as responsive to Kalydeco (see Related Information) AND documentation of at least one copy of the CFTR gene mutation is provided AND does not have liver function tests (LFT) above 3X upper limit of normal (ULN) AND Kalydeco will not be used in combination with Alyftrek, Orkambi, Symdeko, or Trikafta AND dose is limited to 2 tablets OR 2 packets daily
Kalydeco is considered not medically necessary when used in individuals homozygous for F508del
Orkambi (lumacaftor/ivacaftor) — Initial therapy
Covered when ALL of the following are met
Orkambi initial criteria: The individual is aged 1 year and older AND is homozygous for the F508del mutation in the CFTR gene AND does not have liver function tests (LFT) above 3X upper limit of normal (ULN) AND Orkambi will not be used in combination with Alyftrek, Kalydeco, Symdeko, or Trikafta
Adhere to product prescribing information for dosing and quantity limits
Symdeko (tezacaftor/ivacaftor) — Initial therapy
Covered when ALL of the following are met
Symdeko initial criteria: The individual is aged 6 years and older AND is homozygous for F508del OR heterozygous for F508del with a residual function mutation OR has at least one CFTR mutation responsive to Symdeko or subsequently added to the FDA-approved indication (see Related Information) AND does not have liver function tests (LFT) above 3X upper limit of normal (ULN) AND Symdeko will not be used in combination with Alyftrek, Kalydeco, Orkambi, or Trikafta
R117H was removed from Symdeko responsive list in 2020; verify genotype against current prescribing information
Trikafta initial criteria: The individual is aged 2 years and older AND has at least one F508del mutation in the CFTR gene OR a CFTR mutation responsive to Trikafta based on clinical and/or in vitro data (see Related Information) AND does not have liver function tests (LFT) above 3X upper limit of normal (ULN) AND Trikafta will not be used in combination with Alyftrek, Kalydeco, Orkambi, or Symdeko AND dose is limited to 3 tablets OR 2 packets daily
Initial authorizations may be issued for up to 12 months per 2026 update; adhere to product prescribing information for dosing
Mutation-to-drug responsiveness lists
Covered when mutation is listed as responsive to the specified CFTR modulator
Alyftrek responsive mutations: The individual's CFTR mutation is listed as responsive to Alyftrek based on in vitro data or extrapolation as enumerated in the policy's mutation tables (see Related Information chunks)
Exact mutation lists are in the policy (chunks 18-23)
Kalydeco responsive mutations: The individual's CFTR mutation is listed among those responsive to Kalydeco per the policy mutation tables or subsequently added to the FDA indication
Exact mutation lists are in the policy (chunks 24-27)
Symdeko responsive mutations: The individual's CFTR mutation is listed among those responsive to Symdeko per the policy mutation tables or subsequently added to the FDA indication
Exact mutation lists are in the policy (chunks 28-33)
Drug-specific efficacy/safety summaries
Evidence-based efficacy and safety findings by drug:
Orkambi efficacy summary: In individuals homozygous for F508del, phase III trials (TRAFFIC/TRANSPORT, total n=1108) over 24 weeks showed modest improvements: ppFEV1 +2.8%, BMI +0.24, CFQR-RD +2.2, and a pulmonary exacerbation rate ratio of 0.61 vs placebo; clinical significance of the absolute FEV1 change is uncertain
Data from 24-week trials in individuals 6 years and older
Symdeko efficacy summary: Phase III trials (EVOLVE and EXPAND) demonstrated modest improvements in ppFEV1 and quality-of-life measures for homozygotes and heterozygotes with residual function mutations; safety was comparable to placebo
EVOLVE: ppFEV1 change ~3.4% at 24 weeks; EXPAND: benefits in heterozygotes
Trikafta efficacy summary: Two pivotal Phase 3 trials in individuals ≥12 years showed large improvements in ppFEV1 (Trial 1: +13.8 pp at Week 4 and +14.3 pp through Week 24 vs placebo; Trial 2: +10.0 pp vs tezacaftor/ivacaftor) with additional improvements in sweat chloride, BMI and CFQ-R scores; pediatric trials focused on safety and biomarker changes
Adverse effects include elevations in ALT/AST in a subset; monitor LFTs
Covered when conditions consistent with FDA labeling and policy updates are met
Policy covers CFTR modulators when used consistent with FDA-approved indications, age limits, mutation responsiveness, and prescribing information.
Age-based approval: Drug must be prescribed consistent with the FDA-labeled minimum age for that product (examples: Kalydeco updated to 1 month; Orkambi to 1 year; Trikafta to 2 years or 6 years depending on prior updates)age per drug labeling
See specific product prescribing information and policy updates
Mutation responsiveness: Coverage requires the individual's CFTR mutation be listed as responsive to the requested modulator; Trikafta coverage includes mutations responsive based on clinical and/or in vitro data per prescribing informationmutation listed in prescribing information or supported by clinical/in vitro data for Trikafta
Provide genetic test documentation as required
Combination prohibition:
All uses of Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), Cayston (aztreonam), Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), or Trikafta (elexacaftor/tezacaftor/ivacaftor) that are for indications or conditions not specifically described in this policy are considered investigational and may be denied.
There are no additional explicit exclusions listed in the cited policy sections beyond the investigational statement above and the drug-specific criteria and mutation lists referenced elsewhere in this policy.
Clinical trial evidence indicates that single‑agent ivacaftor did not produce significant improvement in individuals who are homozygous for the F508del mutation; accordingly, the policy does not support ivacaftor monotherapy for that genotype and explicitly states that Kalydeco is not medically necessary for individuals homozygous for F508del.
The policy documents that in the 2020 update the CFTR mutation R117H was removed from the list of mutations considered responsive to Symdeko (tezacaftor/ivacaftor); as a result, requests relying solely on R117H as the responsive mutation for Symdeko coverage do not meet the responsive‑mutation requirement.
Concurrent use of two or more CFTR modulators listed in this policy is prohibited. The policy clarifies that Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta cannot be used in combination; requests that propose combined use of these agents will not meet coverage criteria and will be denied.
Evidence from a 16‑week ivacaftor trial in individuals homozygous for F508del failed to show meaningful benefit, and the policy explicitly reflects this by indicating that Kalydeco (ivacaftor) is not medically necessary when used in individuals homozygous for F508del.
Within the cited sections there are no standalone statements framed as explicit 'not medically necessary' listings beyond those already specified (for example, Kalydeco in F508del homozygotes).
Requests for ivacaftor products or other CFTR modulators that do not satisfy the policy’s coverage criteria — for example, lacking documentation of a CFTR mutation listed as responsive to the requested agent, not meeting FDA‑labeled age indications, exceeding product quantity limits, or proposing prohibited combinations — may be denied as not meeting medical necessity or as investigational.
Provider Requirements, Prior Authorization, and Documentation
Prior Authorization
Provider Requirements, Prior Authorization, and Documentation
Prior authorization and documentation actions for CFTR modulator therapies. Includes mutation- and age-based coverage, approval durations, contraindicated combinations, investigational uses, documentation and genotype/test requirements, dosing/quantity limits, step-therapy/therapy sequencing considerations, formulary/exception review, and denial triggers.
Mutation- and age-based prior authorization: Coverage is mutation- and age-dependent consistent with FDA labeling; requests must document the individual’s age meets the product-specific FDA indication and list CFTR mutation(s) known to be responsive to the requested product (e.g., F508del or other responsive mutations for Alyftrek or Trikafta). (See responsive mutation lists.)
Initial authorization length: Initial approvals may be granted for up to 12 months. Re-authorization may be approved up to 12 months when documentation shows criteria continue to be met and the member has demonstrated improvement or stabilization in FEV1, symptoms, or disease course.
Contraindicated combinations: Use of two CFTR modulators together is not permitted. Requests proposing combination therapy (e.g., Alyftrek with Trikafta, Kalydeco, Orkambi, or Symdeko; or any other listed CFTR modulator combinations) will be denied.
Investigational uses: All uses of the listed medications for indications not outlined in this policy are considered investigational and may be denied.
No explicit automatic approval/denial without documentation: There are no blanket automatic approvals; authorization/denial decisions require submission of the documentation elements and meeting the coverage criteria.
Coding
Coding sectionmixed
No codes listed
Background and Rationale
Cystic fibrosis is caused by pathogenic variants in the CFTR gene that lead to abnormal ion transport and thickened secretions in the lungs and other organs. CFTR modulators (potentiators and correctors such as ivacaftor, tezacaftor, lumacaftor, elexacaftor, and newer combinations) are targeted therapies designed to improve CFTR protein function and mitigate disease manifestations. This policy defines coverage when use is consistent with FDA‑approved indications, specified responsive CFTR mutations, age limits, laboratory thresholds (e.g., LFTs ≤ 3x ULN), product quantity limits, and the prohibition on concurrent use of listed modulators.
Definitions
CFTR modulators — definition
DefinitionDrugs developed to target specific changes in the CFTR gene to improve CFTR protein function and mitigate cystic fibrosis manifestations.
MechanismModulators act on CFTR protein to increase its function — e.g., potentiate channel gating or improve trafficking to the cell surface.
PurposeUsed to treat cystic fibrosis when a patient has CFTR mutations listed as responsive to the specific modulator per prescribing information and policy criteria.
‘Responsive based on clinical data’ — Trikafta annotation meaning
Annotation meaning‘Responsive based on clinical data’ indicates the mutation has documented patient-level clinical responsiveness to Trikafta as listed in the policy’s Trikafta mutation table.
Implication for coverage
Revision History and Policy Changes
2026-04-01policy_revisionLatest
Updated initial authorization length for CFTR modulators and related drugs from 6 months to 12 months (initial approvals may be issued up to 12 months).
2025-11-01policy_revision
Added coverage criteria for Alyftrek (vanzacaftor/tezacaftor/deutivacaftor); expanded Trikafta coverage to include certain mutations responsive based on clinical and/or in vitro data; added quantity limits and clarified that listed CFTR modulators cannot be used in combination; clarified non-formulary exception review authorizations may be approved up to 12 months.
Policy Summary
PayerPremera Bluecross
PolicyPharmacologic Treatment of Cystic Fibrosis
Policy CodePolicy N/A
Change TypeMaterial updates to coverage criteria and authorization length
Effective DateApr. 1, 2026
Next Review DateN/A
Key ActionObtain and submit CFTR genotype documentation showing a mutation listed as responsive to the requested CFTR modulator for prior authorization.
The individual's CFTR mutation is listed among those responsive to Trikafta based on clinical and/or in vitro data as enumerated in the policy mutation tables
Exact mutation lists and annotations are in the policy (chunks 34-37)
Alyftrek, Kalydeco, Orkambi, Symdeko, and Trikafta cannot be used concurrently with one another
no concurrent use
Requests that combine listed modulators will be denied
Quantity limits: Product-specific quantity limits per FDA prescribing information apply and will be enforcedproduct-specific quantity limits
Exceeding quantity limits may result in denial
Authorization duration: Initial approvals may be issued for up to 12 months (updated from 6 months)initial approval = 12 months
Reauthorization requires documentation that criteria continue to be met and clinical benefit or stabilization
Mutation not on responsive list: Lack of documentation of a CFTR mutation known to be responsive to the requested product may result in denial.
Mutation-specific coverage risk: Products with mutation-specific changes (e.g., removal of R117H for Symdeko) will be evaluated against the current responsive-mutation lists; sole listing of excluded mutations may result in noncoverage.
Quantity limit exceedance: Requests exceeding product-specific quantity limits per prescribing information (e.g., tablet/packet limits) may be denied.
Required medical record elements: Submit office visit notes with diagnosis, relevant history, physical exam, medication history, results of CFTR gene mutation testing, and any relevant laboratory results (e.g., liver function tests).
Genetic test documentation: Provide CFTR genetic test results enumerating the identified mutations; include test report and date of testing.
Genotype documentation: Historical genotype documentation is required when available; if genotype is unknown, CFTR mutation testing should be completed and documented.
Dosage documentation: Dosing must follow the product’s FDA dosage and administration prescribing information; quantity requests should match labeled dosing and any plan quantity limits.
Step therapy considerations: While newer agents (e.g., Alyftrek) and alternatives (e.g., Trikafta) are recognized, no blanket step-therapy ordering is mandated in this policy; documentation of prior use, intolerance, or contraindication to other agents may be requested when clinically relevant.
Therapy sequencing/alternatives: Therapy choice should be aligned with the individual’s CFTR genotype and age per labeling; alternatives may be appropriate for specific mutation profiles.
Formulary/exception management: Non-formulary exception review authorizations may be approved up to 12 months; quantity limits and formulary status will be enforced per prescribing information and plan rules.
Mutations with this annotation are eligible for Trikafta coverage when other policy criteria (age, LFTs, non‑combination) are met.
Source notePolicy expanded Trikafta coverage in 2025 to include mutations responsive based on clinical and/or in vitro data; see prescribing information referenced in the policy.
‘Responsive based on in vitro data’ — definition
Annotation meaning‘Responsive based on in vitro data’ denotes laboratory (cell-based) evidence showing the CFTR variant responds to Trikafta in vitro, as documented in the prescribing information and included in the policy’s mutation tables.
Implication for coverageMutations with this annotation may be considered for Trikafta when clinical criteria are met and mutation documentation provided.
Policy historyThe 2021 update added coverage for Trikafta mutations responsive based on in vitro data for individuals aged 6 years and older (per prescribing information).
‘Based on Extrapolation’ — Alyftrek annotation meaning
Annotation meaning‘Based on Extrapolation’ indicates inferred responsiveness to Alyftrek derived from related variants or available data rather than direct clinical or in‑vitro evidence for that exact variant.
Coverage implicationEntries marked ‘Based on Extrapolation’ are included in Alyftrek’s responsive mutation list in the policy but reflect inferred, not directly observed, responsiveness.
Source exampleThe Alyftrek mutation table contains multiple entries expressly labeled as ‘Based on Extrapolation’ (see policy mutation listings).
F508del — definition and significance
DefinitionF508del (ΔF508) is a deletion of three nucleotides that results in loss of phenylalanine at position 508 of CFTR.
SignificanceF508del causes defective CFTR protein folding, retention and degradation inside the cell, leading to little or no CFTR at the cell surface and severe reduction in chloride transport.
EpidemiologyΔF508 accounts for approximately 66–70% of CF cases worldwide and is the most common CFTR mutation.
Gating mutation (e.g., G551D) — brief definition
DefinitionA gating mutation (example G551D) is an amino acid substitution in the nucleotide‑binding domain that markedly reduces CFTR channel gating activity without necessarily reducing channel number at the membrane.
Functional effectGating mutations impair ATP binding/hydrolysis-driven opening of the CFTR pore, decreasing ion flow despite channels being present at the cell surface.
Clinical relevanceGating mutations (e.g., G551D) are responsive to potentiator therapy such as ivacaftor which improves channel opening.
CFTR modulator (combination) — definition of correctors and potentiator combinations
DefinitionCombination CFTR modulators pair one or more correctors (elexacaftor, tezacaftor, lumacaftor, vanzacaftor, deutivacaftor) with a potentiator (ivacaftor) to increase both quantity and function of CFTR at the cell surface.
MechanismCorrectors improve cellular processing and trafficking of misfolded CFTR (e.g., F508del) to the cell surface; potentiators enhance channel gating once at the membrane.
ExamplesTrikafta combines elexacaftor + tezacaftor (correctors) with ivacaftor (potentiator); Alyftrek is a combination of vanzacaftor + tezacaftor + deutivacaftor plus ivacaftor component in fixed-dose formulations per prescribing information.
CFTR modulator agents — ivacaftor-containing products and other modulators
Ivacaftor-containing productsKalydeco (ivacaftor) — potentiator used alone for certain gating and other responsive mutations.
Corrector–potentiator combinationsOrkambi (lumacaftor/ivacaftor), Symdeko (tezacaftor/ivacaftor), Trikafta (elexacaftor/tezacaftor/ivacaftor), Alyftrek (vanzacaftor/tezacaftor/deutivacaftor combinations) — combine correctors with ivacaftor to address misfolding and gating.
Policy inclusionThe policy lists these agents and specifies mutation‑ and age‑based coverage criteria, quantity limits, and a prohibition on using listed modulators in combination with one another.
Prescribing informationCoverage and responsive mutation lists are based on product prescribing information and policy updates (2021–2025 updates clarified in the policy).
2023
label_alignment
Updated age indications per FDA labeling: Kalydeco to 1 month and Trikafta to 2 years (policy updated to reflect these FDA label changes).
2022label_alignment
Updated Orkambi (lumacaftor/ivacaftor) approval age to 1 year per FDA labeling and reflected that change in policy criteria.
2020criteria_revision
Removed CFTR gene mutation R117H from the list of mutations responsive to Symdeko (tezacaftor/ivacaftor) per FDA prescribing information update.
2019label_alignment
Reviewed prescribing information and updated Symdeko age indication to 6 years and older in the policy.
2018addition
Added Symdeko (tezacaftor/ivacaftor) as a treatment option with age listed based on FDA labeling; updated Orkambi age to 2 years and Kalydeco age to 1 year at the time of the update and added a table of target mutations for Symdeko.
2016label_alignment
Changed Orkambi age criteria from 12 to 6 years in the policy to match FDA labeling at that time.
date:2015addition
Added new combination product Orkambi (lumacaftor/ivacaftor) to the policy following FDA approval in 2015.